BNTX - BioNTech SE
98.39
-6.960 -7.074%
Share volume: 1,009,157
Last Updated: 03-11-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.00%
PREVIOUS CLOSE
CHG
CHG%
$105.35
-6.96
-0.07%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 05-08-2023 | 08-07-2023 | 11-06-2023 | 03-20-2024 | 05-06-2024 | |
| Total revenue | 1.392 B | 182.304 M | 947.257 M | 1.700 B | 202.610 M | |
| Cost of revenue | 104.672 M | 177.086 M | 171.190 M | 210.162 M | 63.829 M | |
| Gross profit | 1.288 B | 5.218 M | 776.067 M | 1.490 B | 138.781 M | |
| -99.59% | 14,772.91% | 92.00% | -90.69% | |||
| Operating expenses | 507.659 M | 558.977 M | 694.916 M | 826.319 M | 691.315 M | |
| Selling general and admin | 143.488 M | 153.061 M | 168.121 M | 151.895 M | 143.209 M | |
| Research and development | 364.171 M | 405.916 M | 526.795 M | 674.424 M | 548.105 M | |
| Total expenses | 612.331 M | 736.063 M | 866.106 M | 1.049 B | 755.143 M | |
| 20.21% | 17.67% | 21.15% | -28.03% | |||
| Operating income | 780.024 M | -553.759 M | 81.151 M | 650.875 M | -552.533 M | |
| Ebit | 780.024 M | -553.759 M | 81.151 M | 650.875 M | -552.533 M | |
| Pretax income | 771.629 M | -448.095 M | 240.597 M | 747.163 M | -358.347 M | |
| -158.07% | -153.69% | 210.55% | -147.96% | |||
| Income tax | 224.063 M | -241.115 M | 70.677 M | 229.174 M | -18.036 M | |
| Net income basic | 547.565 M | -206.980 M | 169.920 M | 517.988 M | -340.311 M | |
| -137.80% | 182.09% | 204.84% | -165.70% | |||
| Net income | 547.565 M | -206.980 M | 169.920 M | 517.988 M | -340.311 M | |
| -137.80% | 182.09% | 204.84% | -165.70% |